**Abstract**

**Background:** Since 1962, enterovirus D68 (EV-D68) has been implicated in multiple outbreaks and sporadic cases of respiratory infection worldwide, especially in the USA and Europe with an increasing frequency between 2010 and 2014. We describe the detection, associated clinical features and molecular characterization of EV-D68 in central and southern Viet Nam between 2009 and 2015.

**Methods:** Enterovirus/rhinovirus PCR positive respiratory or CSF samples taken from children and adults with respiratory/central nervous system infections in Viet Nam were tested by an EV-D68 specific PCR. The included samples were derived from 3 different observational studies conducted at referral hospitals across central and southern Viet Nam 2009-2015. Whole-genome sequencing was carried out using a MiSeq based approach. Phylogenetic reconstruction and estimation of evolutionary rate and recombination were carried out in BEAST and Recombination Detection Program, respectively.

**Results:** EV-D68 was detected in 21/625 (3.4%) enterovirus/rhinovirus PCR
EV-D68 was detected in 21/625 (3.4%) enterovirus/rhinovirus PCR positive respiratory samples but in none of the 15 CSF. All the EV-D68 patients were young children (age range: 11.8 – 24.5 months) and had moderate respiratory infections. Phylogenetic analysis suggested that the Vietnamese sequences clustered with those from Asian countries, of which 9 fell in the B1 clade, and the remaining sequence was identified within the A2 clade. One intra sub-clade recombination event was detected, representing the second reported recombination within EV-D68. The evolutionary rate of EV-D68 was estimated to be 5.12E-3 substitutions/site/year. Phylogenetic analysis indicated that the virus was imported into Viet Nam in 2008.

**Conclusions:** We have demonstrated for the first time EV-D68 has been circulating at low levels in Viet Nam since 2008, associated with moderate acute respiratory infection in children. EV-D68 in Viet Nam is most closely related to Asian viruses, and clusters separately from recent US and European viruses that were suggested to be associated with acute flaccid paralysis.

**Keywords**
Enterovirus D68, respiratory infections, VIZIONS, next generation sequencing, Vietnam

This article is included in the Oxford University Clinical Research Unit (OUCRU) gateway.

**Corresponding authors:** Catherine Anscombe (canscombe@oucru.org), Tan Le Van (tanlv@oucru.org)

**Competing interests:** No competing interests were disclosed.

**How to cite this article:** Ny NTH, Anh NT, Hang VTT et al. Enterovirus D68 in Viet Nam (2009-2015) [version 1; referees: 2 approved, 1 approved with reservations] Wellcome Open Research 2017, 2:41 (doi: 10.12688/wellcomeopenres.11558.1)

**Copyright:** © 2017 Ny NTH et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Grant information:** This work was supported by the Wellcome Trust, UK [101104/Z/13/Z, 106680/B/14/Z, 093724/Z/10/Z and 204904/Z/16/Z]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**First published:** 15 Jun 2017, 2:41 (doi: 10.12688/wellcomeopenres.11558.1)
Introduction
Enterovirus D68 (EV-D68) is a genotype of Enterovirus D, a species within the genus Enterovirus, family Picornaviridae. It was initially isolated in 1962 from children with bronchitis/pneumonia in California, USA. EV-D68 shares numerous properties with rhinoviruses, including its association with respiratory rather than systemic infections and, unlike other enterovirus A–D genotypes, its 5’ UTR end. EV-D68 can be further divided into clades A, B and C and these can be further divided into subclades (e.g., A1, A2).

Since 1962, EV-D68 has been implicated in multiple small outbreaks and sporadic cases of respiratory infection worldwide, with the associated clinical syndromes ranging in severity from mild to severe. However, between 2010 and 2014 EV-D68 was reported to the Centers of Disease Control and Prevention in the USA (USCDC) at much higher frequency than in previous years: 1153 cases were confirmed, predominantly among children and often in a context of asthma and wheezing. A simultaneous increase in numbers of cases of acute flaccid paralysis was reported, and although an epidemiological link seems possible, a virological association between these events has not yet been proven.

Genomic investigation of the causative viruses of those outbreaks in the USA showed that the EV-D68 belonged to the subclade B1. Increased detections of EV-D68 were also reported in both children and adults from Europe and the Asia-Pacific region during the 2014–2015 period.

Given the emergence and potential public health threat of EV-D68, improving our knowledge about the geographic distribution, evolution and associated clinical phenotypes of the virus is essential for future intervention strategies and outbreak response. Here we describe the detection, associated clinical features and molecular characterization of EV-D68 infection, using respiratory and cerebrospinal fluid (CSF) samples from children in central and southern Vietnam between 2009 and 2015.

Methods
Clinical samples
Clinical samples were selected from three different studies previously conducted in Vietnam. The first cohort involved children under two years of age with lower respiratory tract infections admitted to two large paediatric hospitals (Children’s Hospital 1 and 2, Ho Chi Minh City) between 2009 and 2010 (n=632, median age: 7 months, interquartile range (IQR): 4 – 12). The second cohort involved children with respiratory infections visiting the outpatient department of Children’s Hospital 1 between 2009 and 2010 (n=563; median age: 1.96 years, IQR: 1.05 – 3.18). The third cohort involved children and adults hospitalised with respiratory or central nervous system infections, admitted to five major hospitals in central and southern Vietnam between 2013 and 2016, with respiratory samples (n=3791, median age: 2 years, IQR: 1 – 4) and CSF samples (n=877, median age: 17 years, IQR: 5 – 44) being taken. The five hospitals in Vietnam included: i) Dong Thap General Hospital, Dong Thap province, ii) Hue Central Hospital, Hue City, iii) Dak Lak General Hospital, Ban Me Thuot City, iv) Khanh Hoa General Hospital, Nha Trang City, and v) Hospital for Tropical Diseases, Ho Chi Minh City.

Ethics
All studies were approved by the corresponding institutional review board of the local hospitals in Vietnam where patients were enrolled:

(i) Children Hospital 1, Ho Chi Minh City (approval numbers 430BVND and 146/BVND1-KHKT);
(ii) Hue Central Hospital, Hue City (77/25/05/12);
(iii) Dak Lak General Hospital, Ban Me Thuot City (489/BVT-KHTH);
(iv) Khanh Hoa General Hospital, Nha Trang City (356/BVDKT);
(v) Hospital for Tropical Diseases, Ho Chi Minh City (136/BVBNĐ – KH);
(vi) Children Hospital 2, Ho Chi Minh City,
(vii) Dong Thap General Hospital, Dong Thap province (approval number not available; signed date: 5/6/12).

The study was also approved by the Oxford Tropical Research Ethics Committee (31-08, 44-08 and 15-12).

Written informed consent was obtained from either the participant, or the participant’s parent or legal guardian.

Enterovirus D68 detection and whole genome sequencing
From the above described cohorts, archived respiratory samples and CSF were screened using a 5’ UTR PCR, those that were enterovirus or rhinovirus PCR positive were selected for further testing by EV-D68 viral specific PCR. EV-D68 real time specific reverse-transcriptase PCR was carried out as previously described.

EV-D68 positive specimens with a Ct-value of 32 or less were subjected to whole genome sequencing using MiSeq platform (Illumina, San Diego, CA, USA) and a non-ribosomal random PCR approach as previously described.

Sequence analysis
The generated sequencing data from Illumina MiSeq was first subjected to a primer removing step using standard parameters available in Geneious software version 8.1.5 (Biomatters, Ltd, Auckland, New Zealand) and a reference based mapping approach was then employed to assemble the viral genomes, followed by manual editing of the obtained consensuses using Geneious. Samples where the full VP1 regions or whole genomes were successfully sequenced proceeded to recombination detection and phylogenetic analysis.

Recombination detection and phylogenetic analysis
All sequence alignment was carried out using MUSCLE, available in Geneious (Biomatters).

Recombination was inferred using a combination of methods (Chimera, GENECONV, Maxchi, Bootscan and Siscan) within RDP4 (Recombination Detection Program, version 4), with
recombination supported if more than three methods showed significant values. The recombination event was then confirmed by constructing a neighbor-joining tree using the group D enterovirus sequences. Identified recombined samples were removed from further phylogenetic analysis.

The origin, evolution rate and divergence time of EV-D68 were estimated by using representatives of VP1 sequences (n=124) and whole genome sequences (n=58), downloaded from GenBank (Supplementary Table 1 and Supplementary Table 2) alongside the Vietnamese sequences recovered in the present study. All analyses were carried out in BEAST version 1.8.3 using the General Time Reversible (GTR) with gamma 4 nucleotide substitution model and the strict molecular clock model.

Sequence accession numbers
The sequences of EV-D68 obtained in this study were submitted to NCBI under accession numbers MF045413–MF045423.

Results
Of a total 5863 samples (4986 respiratory samples and 877 CSF), 639 (624 respiratory, 15 CSF) were positive for enterovirus or rhinovirus by PCR on initial screening. EV-D68 was subsequently detected in 21 of 624 (3.4%) of enterovirus/ rhinovirus positive respiratory samples, while no CSF samples were positive for EV-D68. Overall, EV-D68 was detected in 0.4% of 5863 tested samples, and 3.3% of 639 enterovirus/ rhinovirus positive respiratory/CSF samples.

Demographics and clinical features
Table 1 briefly summarises the demographics, presenting features and outcomes for all 21 EV-D68 PCR positive patients. All 21 patients in whom EV-D68 was detected were aged 2 years or less, with a median age of 17 months at time of presentation. Three were admitted to the outpatient department of Children’s Hospital 1 (the second cohort), and the remaining 18 were inpatients enrolled into the first and the third cohorts. One patient had a pre-existing neurological comorbidity; the remaining 20 children were healthy at baseline.

All 21 patients presented with an acute respiratory illness of short duration (median onset 2 days prior to admission), and the median temperature at presentation was 38°C (range: 37.5°C – 38.4°C) (Table 1). No patient required admission to intensive care. All of the patients survived their infection, and 16 (76%) had recovered completely at the time of discharge. The nature of the residual symptoms in the remaining 5 patients was not available. There were no reported cases of acute flaccid paralysis in this case series.

Whole genome sequencing
In total, 15 samples were processed for whole genome sequencing; of these, 9 samples gave genome coverage of over 89% (Table 2), with the uncovered sections being mainly confined to the 5’ end of the genome. Two additional samples gave complete coverage of the VP1 region.

Recombination detection
One recombination event was detected, in sample EVD68-VN5, with the recombination being intra-sub-clade, within B1 (Figure 1). The recombination event occurred between nucleotide 3500 and 6300, with the sequence assembly depth remaining at about 1000 across the whole genome and phylogenetic tree, with a change in topological position within the B1 clade supported by the recombination event (Figure 1C). Sample EVD68-VN5 was therefore removed from subsequent phylogenetic inference.

Table 1. Demographics, clinical features and outcome for 21 patients with EV-D68 PCR positive respiratory specimens.
Categorical data were presented as n (%). Continuous variables were presented as median (range).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (months)</td>
<td>17.2 (11.8-24.5)</td>
<td></td>
</tr>
</tbody>
</table>

Clinical features

<table>
<thead>
<tr>
<th>Characteristics</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute respiratory illness</td>
<td>21</td>
</tr>
<tr>
<td>Duration of symptoms prior to admission (days)</td>
<td>2 (2-3)</td>
</tr>
<tr>
<td>Fever</td>
<td>13 (61.9)</td>
</tr>
<tr>
<td>Temperature at presentation</td>
<td>38.0 (37.5-38.4)</td>
</tr>
<tr>
<td>Haematology results</td>
<td></td>
</tr>
<tr>
<td>Haemoglobin (g/dL)</td>
<td>11.2 (10.3-12.0)</td>
</tr>
<tr>
<td>Leucocyte count ×10^9/L</td>
<td>13.6 (10.9-16.5)</td>
</tr>
<tr>
<td>Neutrophils % total</td>
<td>57.3 (37.8-64.9)</td>
</tr>
<tr>
<td>Lymphocytes % total</td>
<td>30.45 (22.5-43)</td>
</tr>
<tr>
<td>Eosinophils % total</td>
<td>0.25 (0.2-1.9)</td>
</tr>
<tr>
<td>Platelets</td>
<td>347 (316-377)</td>
</tr>
<tr>
<td>Discharge outcome*</td>
<td></td>
</tr>
<tr>
<td>Complete recovery</td>
<td>16 (76.2)</td>
</tr>
<tr>
<td>Residual symptoms</td>
<td>5 (23.8)</td>
</tr>
<tr>
<td>Death</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

Table 2. Results of reference mapping to EV-D68 genome of the 11 EV-D68 whole genome samples.

<table>
<thead>
<tr>
<th>Sample ID</th>
<th>% Genome coverage</th>
<th>Accession numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVD68-VN1</td>
<td>89.2006</td>
<td>MF045413</td>
</tr>
<tr>
<td>EVD68-VN2</td>
<td>89.1597</td>
<td>MF045414</td>
</tr>
<tr>
<td>EVD68-VN3</td>
<td>89.187</td>
<td>MF045415</td>
</tr>
<tr>
<td>EVD68-VN4</td>
<td>89.3095</td>
<td>MF045416</td>
</tr>
<tr>
<td>EVD68-VN5</td>
<td>89.1597 (recombinant)</td>
<td>MF045417</td>
</tr>
<tr>
<td>EVD68-VN6</td>
<td>89.2006</td>
<td>MF045418</td>
</tr>
<tr>
<td>EVD68-VN7</td>
<td>89.1597</td>
<td>MF045419</td>
</tr>
<tr>
<td>EVD68-VN8</td>
<td>80.4712</td>
<td>MF045420</td>
</tr>
<tr>
<td>EVD68-VN9</td>
<td>89.4049</td>
<td>MF045421</td>
</tr>
<tr>
<td>EVD68-VN10</td>
<td>89.187</td>
<td>MF045422</td>
</tr>
<tr>
<td>EVD68-VN11</td>
<td>69.6037</td>
<td>MF045423</td>
</tr>
</tbody>
</table>
Figure 1. Recombination analysis of EVD68-VN9. (A) Similarity plot analysis of EVD68-VN5 against the two heterogenic parents, EVD68-VN3 (blue) and EVD68-VN7 (purple). The x-axis indicates the number of nucleotides along the alignment, the y-axis indicates percentage similarity. (B) Bootscan plot analysis supporting for the recombination event of EVD68-VN5 detected by similarity plot analysis in (A). The y-axis indicates the percentage of bootstrap values. (C) Phylogenetic analyses of nonrecombinant fragments of representatives of clade B1; the putative recombinant strain is in red.
Phylogenetic analysis and evolutionary rate of EV-D68

9 out of 10 Vietnamese EV-D68 VP1 sequences fell in the B1 clade (Figure 2), and the remaining sequence was identified within the A2 clade. In all cases, the Vietnamese sequences clustered with Asian viruses. Whilst the Vietnamese viruses were not monophyletic, seven of the B1 sequences had other Vietnamese sequences as their closest relatives. Phylogenetic analysis also suggests multiple introductions to Viet Nam, with the first introduction being no later than 2008 (Figure 2). Similar results were obtained when the analysis was carried out at whole genome level (Figure 3), with the exception that a single sequence from the A2 clade was introduced earlier (2006).

The rate of evolution of EV-D68 was calculated from the VP1 data as 5.12E⁻³ substitutions/site/year. Bayesian analysis suggests that the EV-D68 origin lies in late 1960, and the common ancestor of the lineages under-investigation arose in 1994.

Discussion

Herein we have described for the first time the clinical presentation and phylogenetic characterization of EV-D68 in Viet Nam for the period 2009 to 2015.

Of 639 patients whose nasopharyngeal or CSF sample tested positive for enterovirus or rhinovirus on multiplex PCR, 21 (3.2%) respiratory samples were found to be positive for EV-D68 on specific RT-PCR. Overall, of 4986 respiratory samples screened, 0.4% were positive for EV-D68. This indicates that EV-D68 has been circulating at low levels in Viet Nam between 2009 and 2015; however, it does not represent a major contribution to the burden of acute respiratory illness in the region, in line with findings by Nguyen et al. that show enteroviruses only account for 5% of respiratory illness in Viet Nam²¹.

All of 21 EV-D68 positive patients were aged less than 2 years, presented with moderate respiratory illness and none needed admission to intensive care units. This is consistent with the findings of Xiang et al.²² who reported that EV-D68 infection predominantly caused non-severe respiratory illness in children in China between 2006 and 2014, but differs from reports from Thailand and Cambodia, where EV-D68 positive patients were mostly older children and adults, respectively²³,²⁴. It should be noted, however, that the majority of our patients were children, which may explain the difference. Likewise, it has recently been reported in the Netherlands that EV-D68 was associated with severe respiratory

---

**Figure 2.** MCC tree from Bayesian timescale phylogenetic analysis based on complete VP1 nucleotide sequence (927nt) of EV-D68 including Vietnamese strains obtained from this study (dark blue) and global representatives retrieved from GenBank.
infection in young children, however most of these patients had pulmonary co-morbidity at baseline.

Our phylogenetic analysis puts the identified Vietnamese EV-D68 in a global context and shows that the EV-D68 viruses circulating in Viet Nam belong to subclade B1, which includes EV-D68 viruses sampled across various continents including Asia, Europe and America. Our Vietnamese viruses are, however, most closely related to other Asian strains, and cluster separately within subgroup B1 from those which have been associated with epidemic outbreaks and implicated in acute flaccid paralysis in the USA in children with a median age of 8 years. It should however be noted that to date there has been no definitive link between specific EV-D68 strains and clinical phenotypes. Likewise, the causative role of EV-D68 in acute flaccid paralysis remains unproven.

Interestingly, we report herein a recombination event within our EV-D68 whole genome data set. This represents the second reported recombination within EV-D68, although recombination is a common phenomenon of enterovirus evolution.

The non-monophyletic clustering pattern suggests that EV-D68 was introduced in Viet Nam multiple times, while the low-level clustering suggests some persistence within Viet Nam, with no outbreak reported until now. Our data agrees with other published estimates of the origin and evolution rate of EV-D68.

Conclusion
We have demonstrated that EV-D68 has been circulating at low levels in Viet Nam in the period of 2009 to 2015, and is associated with a moderate acute respiratory infection in healthy children in
our cohorts. EV-D68 in Viet Nam is most closely related to other circulating Asian strains, and clusters separately from those implicated to be associated with acute flaccid paralysis in the USA and Europe.

Data availability
The sequences of EV-D68 obtained in this study were submitted to NCBI under accession numbers MF045413–MF045423.

Author contributions
LVT, GT, NVVC, and H.RvD designed the study. NTHN, NTA, VTTH, AM, DTH, CA, PTTT, TMP, DQH; performed data analysis. NNQM, DLAH, HMT, SB, TQL, NTAV, NVH, TTTM, NVX, ND, HDTN, NVVC, enrolled the patients and collected data. NTHN, AM, CA, and LVT drafted the manuscript. All authors have read the final manuscript and agreed with its contents.

Competing interests
No competing interests were disclosed.

Grant information
This work was supported by the Wellcome Trust, UK [101104/Z/13/Z, 106680/B/14/Z, 093724/Z/10/Z and 204904/Z/16/Z]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements
The VIZIONS Consortium members (alphabetical order by surname), from the Oxford University Clinical Research Unit are: Bach Tuan Kiet, Stephen Baker, Alessandra Berto, Maciej F. Boni, Juliet E. Bryant, Bui Duc Phu, James I. Campbell, Juan Carrique-Mas, Dang Manh Hung, Dang Thao Huong, Dang Tram Oanh, Jeremy N. Day, Dinh Van Tan, H. Rogier van Doorn, Duong An Han, Jeremy J. Farrar, Hau Thi Thu Trang, Ho Dang Trung Nghia, Hoang Bao Long, Hoang Van Duong, Huynh Kim Tho, Lam Chi Cuong, Le Manh Hung, Le Thanh Phuoc, Le Thi Phuc, Le Thi Phuong, Le Xuan Luat, Luu Thi Thu Ha, Ly Van Chuong, Mai Thi Phuc Loan, Behzad Nadjam, Ngo Thanh Bao, Ngo Thi Hoa, Ngo Tri Tue, Nguyen Canh Tu, Nguyen Dac Thuan, Nguyen Dong, Nguyen Khac Chuyen, Nguyen Ngoc An, Nguyen Ngoc Vinh, Nguyen Quoc Hung, Nguyen Thanh Dung, Nguyen Thanh Minh, Nguyen Thi Binh, Nguyen Thi Hong Tham, Nguyen Thi Hong Tien, Nguyen Thi Kim Chuc, Nguyen Thi Le Ngoc, Nguyen Thi Lien Ha, Nguyen Thi Nam Lien, Nguyen Thi Ngoc Diep, Nguyen Thi Nhung, Nguyen Thi Song Chau, Nguyen Thi Yen Chi, Nguyen Thieu Trinh, Nguyen Thu Van, Nguyen Van Cuong, Nguyen Van Hung, Nguyen Van Kinh, Nguyen Van Minh Hoang, Nguyen Van My, Nguyen Van Thang, Nguyen Van Thanh, Nguyen Van Vinh Chau, Nguyen Van Xang, Pham Ha My, Pham Hong Anh, Pham Thi Minh Khoa, Pham Thi Thanh Tam, Pham Van Lao, Pham Van Minh, Pham Van Be Bay, Maia A. Rabaa, Motiur Rahman, Corinne Thompson, Guy Thwaites, Ta Dieu Ngan, Tran Do Hoang Nhu, Tran Hoang Minh Chau, Tran Khanh Toan, Tran My Phuc, Tran Thi Kim Hong, Tran Thi Ngoc Dung, Tran Thi Thanh Thanh, Tran Thi Thuy Minh, Tran Thua Nguyen, Tran Tinh Hien, Trinh Quang Tri, Vö Be Hien, Vo Nhu Tai, Vo Quoc Cuong, Voong Vinh Phat, Vu Thi Lan Huong, Vu Thi Ty Hang, and Heiman Wertheim; from the Centre for Immunity, Infection, and Evolution, University Of Edinburgh: Carlijn Bogaardt, Margo Chase-Topping, Al Ivens, Lu Lu, Dung Nguyen, Andrew Rambaut, Peter Simmonds, and Mark Woolhouse; from The Wellcome Trust Sanger Institute, Hinxton, United Kingdom: Matthew Cotten, Bas B. Oude Munnink, Paul Kellam, and My Vu Tra Phan; from the Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands: Martin Deijs, Lia van der Hoek, Maarten F. Jebbink, and Seyed Mohammad Jazaeri Farsani; and from Metabiota, CA: Karen Saylor and Nathan Wolfe.

Supplementary materials
Supplementary Table 1: Accession numbers, locations and sampling dates of representatives of VP1 sequences.
Click here to access the data.

Supplementary Table 2: Accession numbers, locations and sampling dates of representatives of whole genome sequences used for the analysis.
Click here to access the data.

References


3. Oberste MS, Maher K, Schnurr D, et al.: Enterovirus 68 is associated with


Open Peer Review

Current Referee Status:  ✔  ✔  ✔

Version 1

Referee Report 07 August 2017

doi:10.21956/wellcomeopenres.12486.r24362

Hitoshi Oshitani
Department of Virology, Tohoku University Graduate School of Medicine, Sendai, Japan

The manuscript is well written and technically sound. But I have a few minor comments which might be helpful to improve the manuscript.

1. In the introduction, the authors mentioned that EV-D68 is a genotype. It is true that typing of enteroviruses including EV-D68 is currently done mainly by genetic analysis. But many of enteroviruses including EV-D68 were originally classified as serotypes by using serological tests. I don’t think a genotype is appropriate.

2. In line 7 of introduction, I am not sure what the authors would like to explain about 5'UTR.

3. They mentioned that all EV-D68 cases had ‘moderate respiratory illness’. But the definition of moderate respiratory illness is unclear.

4. They collected samples from 2009 and 2015. But it is not mentioned in which year EV-D68 were detected.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes
**Competing Interests:** No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

**Referee Report 31 July 2017**

doi:10.21956/wellcomeopenres.12486.r24363

Kristine M. Wylie
Department of Pediatrics and The Genome Institute, Washington University School of Medicine, St. Louis, MO, USA

This is a nicely written report describing Enterovirus D68 prevalence and genome sequences in Vietnam. I have only minor comments.

1. The authors cite a real-time PCR assay that is specific for Enterovirus D68. I believe this paper cites the assay developed by the CDC. If so, the primary CDC reference should be cited. Does this assay detect viruses from all of the clades? If not or if it is unclear, this should be described as a limitation of the study.

2. Some additional details regarding the PCR assay and sequencing assays would be useful for reproducibility. Was there absolutely no deviation from the cited papers? What enzymes were used? RT-PCR instrument? How much material was used as input for the sequencing assays? What were the specific library construction methods?

3. In Figures 2 and 3, it is difficult to distinguish the dark and light blue colors. A color with more contrast should be selected for the Vietnam samples.

4. There seems to be a formatting issue. Sporadically lowercase "f" is replaced with an odd symbol in my copy of the paper. There are several examples in the second paragraph of the introduction, but this occurs elsewhere in the paper, too.

**Is the work clearly and accurately presented and does it cite the current literature?**
Yes

**Is the study design appropriate and is the work technically sound?**
Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Partly

**If applicable, is the statistical analysis and its interpretation appropriate?**
Yes

**Are all the source data underlying the results available to ensure full reproducibility?**
Yes

**Are the conclusions drawn adequately supported by the results?**
Yes

**Competing Interests:** No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Referee Report 25 July 2017
doi:10.21956/wellcomeopenres.12486.r24365

**Weihua Huang**
Department of Pathology, New York Medical College, Vahalla, NY, USA

As I read it, the manuscript needs certain revisions. For example, "Phylogenetic analysis indicated that the virus was imported into Viet Nam in 2008." should be changed to "Phylogenetic analysis suggested that the virus likely appeared in Viet Nam in 2008.". There were also typing errors, such as "Figure 1. Recombination analysis of EVD68-VN9", which should be "EVD68-VN5". In addition, the abbreviation should be given in its full name while it appeared at the first time.

Some suggestions in revision:
1. Table 2 has little to demonstrate and thus could be deleted;

2. Phylogenetic tree on VP1 could be ignored, when more whole genome sequences are available;

3. The detail of isolates should be given in the phylogeny tree for readers to view, and the VN isolates could be colored differently to stand out;

4. With points 2) and 3) taken, the supplementary tables could be deleted;

5. More detail in method will be appreciated, such as sequencing depth, bootstrap numbers for BEAST, and so on.

After all, the manuscript should be more accurate in expression and concise in style.

**Is the work clearly and accurately presented and does it cite the current literature?**
Partly

**Is the study design appropriate and is the work technically sound?**
Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Partly

**If applicable, is the statistical analysis and its interpretation appropriate?**
Partly

**Are all the source data underlying the results available to ensure full reproducibility?**
Yes

Are the conclusions drawn adequately supported by the results?
Partly

**Competing Interests:** No competing interests were disclosed.

**Referee Expertise:** Genomics and transcriptomics in infectious disease and oncology

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.